Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.
Patients with AML in complete remission (CR) are immunosuppressed; remission lymphocytes of at least a part of the patients are able to recognize autologous leukemic blasts; the CR represents a minimal residual disease. Thus, important conditions for a potentially successful active immunotherapy are given. Results of most earlier randomized trials on immunotherapy revealed some, but limited benefit with respect to survival. Encouraging effects, however, have been achieved by immunizing CR patients with high-dose neuraminidase-treated allogeneic blasts. Because these data have not been confirmed until now we recently initiated a randomized study utilizing identical treatment protocols. The preliminary results of the ongoing study still do not allow to draw any firm conclusions. Specific monoclonal antibodies or autologous cytotoxic T-cells may be useful tools for future immunotherapy of AML.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000957:Antigens, Viral, Tumor; D003131:Combined Modality Therapy; D000939:Epitopes; D005544:Forecasting; D006801:Humans; D006968:Hypersensitivity, Delayed; D007108:Immune Tolerance; D007167:Immunotherapy / Q000639:trends; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D013601:T-Lymphocytes / Q000637:transplantation
D000911:Antibodies, Monoclonal; D000957:Antigens, Viral, Tumor; D000939:Epitopes